Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Clinical Efficacy of Retreatment with Venetoclax-based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma
Despite the rapidly evolving therapeutic armamentarium leading to improved survival of patients, multiple myeloma (MM) remains incurable in most cases, emphasizing the urgent need for new therapeutic strategies. It has been observed that patients with MM can overexpress anti-apoptotic proteins, including the B-Cell Leukemia/Lymphoma 2 (BCL-2) protein which promotes tumor proliferation and expansion. 1 BCL-2 upregulation has been primarily observed in patients harboring the translocation between chromosomes 11 and 14 (t[11;14]), which is encountered in 15-20% of MM patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2023 Category: Hematology Authors: Danai Dima, Mark Orland, Fauzia Ullah, Faiz Anwer, Sandra Mazzoni, Shahzad Raza, Chakra P. Chaulagain, Christy Samaras, Jason Valent, Louis Williams, Jack Khouri Tags: Letter to the Editor Source Type: research

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population
In our review of 32 patient with very late relapse occurring>5 years from diagnosis, male gender and increased age were risk factors for inferior survival. ASCT at first relapse had no impact on time to second progression or overall survival from first relapse. Survival outcomes were excellent with overall survival from first relapse of 14.8 years. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2023 Category: Hematology Authors: Hannah Cherniawsky, Esther Ting, Jasper Zhongyuan Zhang, Wei Xu, Anca Prica, Sita Bhella, Chloe Yang, Robert Kridel, Abirami Vijenthira, Vishal Kukreti, Michael Crump, John Kuruvilla Tags: Original Study Source Type: research

Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
: Selinexor is an orally available selective inhibitor of exportin-1 that has offered a new treatment option in relapsed or refractory myeloma (RRMM) either in combination with dexamethasone (Sd) or with bortezomib and dexamethasone (SVd). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2023 Category: Hematology Authors: Efstathios Kastritis, Maria Gavriatopoulou, Eirini Solia, Foteini Theodorakakou, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Nikoleta Kokkali, Evangelos Eleutherakis-Papaiakovou, Rodanthi Syrigou, Despin Tags: Original Study Source Type: research

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population.
Very late relapse (VLR) occurring>5 years after initial diagnosis is an uncommon event in the management of Hodgkin lymphoma (HL). Limited information regarding risk factors and optimal therapy is available.We reviewed patients treated for HL at Princess Margaret Cancer Centre, Toronto, Ontario Canada between January 01, 1999 to 31 December 31, 2018. Thirty-two (32) patients experienced VLR. Median time to first relapse was 7.2 years. Most patients were treated with CMT both at initial diagnosis and relapse. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2023 Category: Hematology Authors: Hannah Cherniawsky, Esther Ting, Jasper Zhongyuan Zhang, Wei Xu, Anca Prica, Sita Bhella, Chloe Yang, Robert Kridel, Abirami Vijenthira, Vishal Kukreti, Michael Crump, John Kuruvilla Tags: Original Study Source Type: research

Multiple Myeloma in Adolescent and Young Adults: An ASCO CancerLinQ and SEER Analysis
RWD from ASCO's CancerLinQ Discovery MM dataset (n  = 1946) and SEER (n = 1334) were used to characterize AYA MM patients. AYAs were more likely to develop ALL, AML, and infections and less likely to develop nonmelanoma skin cancer, prostate cancer, and VTE. Despite a longer OS, most AYAs died of MM (68.3%), other primary malignancy (7.5%, mostl y leukemia), and cardiovascular events (5.2%). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 28, 2023 Category: Hematology Authors: Steven Gibson, Jennifer Thornton, Kevin Sunderland, Kevin Pham, Christin DeStefano Source Type: research

Multiple myeloma (MM) in adolescent and young adults (AYAs): An ASCO CancerLinQ and SEER analysis.
Multiple myeloma (MM) is exceedingly rare in adolescents and young adults (AYAs) (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 28, 2023 Category: Hematology Authors: Gibson SJ, Thornton JA, Sunderland K, Pham K, DeStefano CB Source Type: research

Clinical Application of 18F-FDG-PET Quantification in Hematological Malignancies: Emphasizing Multiple Myeloma, Lymphoma and Chronic Lymphocytic Leukemia
Most hematological malignancies display heightened glycolytic activity, leading to their detectability through 18F-FDG-PET imaging. PET quantification enables the extraction of metabolic information from tumors. Among various PET measurements, maximum standardized uptake value (SUVmax), which indicates the highest value of 18F-FDG uptake within the tumor, has emerged as the commonly used parameter in clinical oncology. This is because of SUVmax ease of calculation using most available commercial workstations, as well as its simplicity and independence from observer interpretation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 28, 2023 Category: Hematology Authors: Mahdi Zirakchian Zadeh Tags: Review Article Source Type: research

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Over the last decade, targeted inhibition of Bruton's tyrosine kinase (BTK) has led to a paradigm shift in the way chronic lymphocytic leukemia (CLL) is managed. BTK inhibitors (BTKi) are broadly classified as covalent BTKI and noncovalent BTKi (cBTKi and ncBTK)Ibrutinib, as the first approved cBTKi, vastly improved outcomes for patients with CLL over prior chemoimmunotherapy regimens. However, long-term use is limited by both intolerance and resistance. The second generation of more selective BTKi were developed to improve tolerability. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 26, 2023 Category: Hematology Authors: Saumya Easaw, Shawyon Ezzati, Catherine C. Coombs Tags: Review Article Source Type: research

Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Over the last decade, targeted inhibition of Bruton's tyrosine kinase (BTK) has led to a paradigm shift in the way chronic lymphocytic leukemia (CLL) is managed. BTK inhibitors (BTKi) are broadly classified as covalent BTKI and non-covalent BTKi (cBTKi and ncBTK)Ibrutinib, as the first approved cBTKi, vastly improved outcomes for patients with CLL over prior chemoimmunotherapy regimens. However, long-term use is limited by both intolerance and resistance. The second generation of more selective BTKi were developed to improve tolerability. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 26, 2023 Category: Hematology Authors: Saumya Easaw, Shawyon Ezzati, Catherine C. Coombs Source Type: research

Utilization of serial next-generation sequencing among patients receiving CPX-351 for newly diagnosed acute myeloid leukemia
The phase III trial that led to the approval of CPX-351 for treating secondary acute myeloid leukemia (sAML) in 2017 did not study the effect of specific mutations on outcomes. This retrospective study was done to evaluate the effect of next-generation sequencing (NGS) results at the time of best response and before allogeneic stem cell transplant (alloSCT) in patients treated with CPX-351 as frontline therapy for sAML between 2017 and 2021. The most common mutations seen were DNMT3A (n  = 17, 29.8%), SRSF2 (n = 13, 22.8%), RUNX1 (n = 13, 22.8%), TET2 (n = 9, 15.8%), ASXL1 (n = 9, 15.8%), and BCOR (n ...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2023 Category: Hematology Authors: Akriti G Jain, Somedeb Ball, Luis E Aguirre, Katherine A Tobon, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David Sallman, Jeffrey E Lancet, Kendra Sweet Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2023 Category: Hematology Source Type: research

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone
Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher incidence of thromboembolic events compared with bortezomib, lenalidomide, and dexamethasone (VRd). We aimed to evaluate VTE risk with KRd induction compared to VRd at a large academic medical center in the United States. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2023 Category: Hematology Authors: Alexa J. Loncharich, Mark A. Fiala, Michael J. Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark A. Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Kristen M. Sanfilippo Tags: Original Study Source Type: research

Effect of the presence of t(11;14) for patients with AL amyloidosis treated with Bortezomib-containing regimens: Experience from the Amyloidosis Program of Calgary
Systemic light-chain amyloidosis (AL amyloidosis) is a proliferative clonal plasma cell disease caused by misfolded proteins forming toxic amyloid light-chain fibrils leading to organ damage.1 The backbone of treatment for transplant-ineligible AL amyloidosis has traditionally involved bortezomib-containing regimens (BCR).2,3 Recent studies involving AL amyloidosis have shown certain cytogenetic aberrations including t(11;14), are associated with sub-optimal responses to bortezomib and perhaps more novel agents such as daratumumab and venetoclax may yield better responses. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 17, 2023 Category: Hematology Authors: Ellen Lewis, Sylvia McCulloch, Etienne Mahe, Nizar Bahlis, Paola Neri, Jason Tay, Peter Duggan, Victor H Jimenez-Zepeda Tags: Letter to the Editor Source Type: research

Real-World Health Care Services Utilization Associated with the Management of Patients with Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study
Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real-world data regarding the utilization of health care services among the relapsed/refractory MM (RRMM) population are scarce. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 14, 2023 Category: Hematology Authors: Enrique M. Ocio, Carmen Montes-Gais án, Gabriela Bustamante, Sebastián Garzón, Esther González, Ernesto Pérez-Persona, Verónica González-Calle, Maialen Sirvent, José M. Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, Marta Grande, Al Tags: Original Study Source Type: research